There is no evidence-based, universally safe starting dose for CJC-1295 and ipamorelin used together. Human research has studied ipamorelin in limited settings, but it does not establish a validated wellness, anti-aging, body-composition, athletic-performance, or combination-peptide starting-dose standard. A number from a chart, calculator, or social-media post cannot replace a licensed clinician’s review.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →How much CJC-1295 and ipamorelin should you start with?
The evidence-based answer is that there is no established starting amount for this combination. A clinician cannot safely turn a general web chart into a personal plan without considering the exact formulation, reason for use, medical history, medicines, and monitoring needs. Recent medical reviews describe important evidence and safety gaps for unapproved peptide therapies. 3 4
It is also important to separate a study dose from a patient instruction. A dose used in a tightly designed trial answers a narrow research question. It does not automatically apply to a different product, a different route, a different goal, or a combination with another peptide.
What research has studied ipamorelin in people?
Ipamorelin, also called NNC 26-0161 in early research, is a growth hormone-releasing peptide and ghrelin mimetic. In a 1999 human-volunteer study, researchers used pharmacokinetic-pharmacodynamic modeling to examine ipamorelin’s relationship with growth hormone secretion. That study supports that ipamorelin has been investigated in people; it does not establish a general wellness dose or a dose for use with CJC-1295. 1
A later randomized proof-of-concept trial evaluated ipamorelin after bowel resection for postoperative ileus, a temporary slowing of bowel function after surgery. That is a very different clinical setting from anti-aging, muscle gain, body composition, or a CJC-1295/ipamorelin combination. 2
What the available evidence does not establish about CJC-1295 plus ipamorelin
The supplied evidence does not establish whether combining CJC-1295, a growth hormone-releasing hormone (GHRH) analog, with ipamorelin is effective or safe for wellness goals. It also does not establish a starting dose, titration schedule, treatment duration, body-weight calculation, or monitoring plan for the pair. Reviews of peptide use in sports medicine and endocrine-related settings emphasize that evidence for many unapproved peptide uses remains limited. 3 4 5 6
Why is there no standard starting dose for the CJC-1295 and ipamorelin combination?
There is no standard because the published and registered human evidence does not validate the combination for the uses commonly discussed online. Two completed phase 2 trials listed on ClinicalTrials.gov studied ipamorelin for postoperative gastrointestinal recovery, not a CJC-1295/ipamorelin wellness protocol. 7 8
A starting dose is not simply a smaller version of a later dose. In clinical practice, a prescribing decision depends on why a medication is being considered, expected benefit, possible harms, other medicines, health conditions, and what follow-up is available. Those questions are especially important where combination-specific human evidence is missing. 3 4
What does a dosing chart for CJC-1295 and ipamorelin actually tell you?
Most online charts show a claimed regimen, not a validated standard of care. A chart alone cannot assess safety for an individual or show that a combination has been tested for the goal being marketed. The evidence supplied for ipamorelin does not validate internet charts for CJC-1295 plus ipamorelin. 1 2 4
Dosing chart: questions an evidence-based chart can and cannot answer
| Question | What the available evidence can support | What it cannot support |
|---|---|---|
| Has ipamorelin been studied in humans? | Yes. Human-volunteer and postoperative studies exist. 1 2 | A universal starting dose for CJC-1295 plus ipamorelin. |
| Have postoperative trials been registered? | Yes. Completed phase 2 trials focused on postoperative gastrointestinal outcomes. 7 8 | Use for anti-aging, athletic performance, or body-composition goals. |
| Can body weight determine a safe dose? | The supplied evidence does not establish a body-weight calculator for the combination. | An individual’s contraindications, interactions, or monitoring needs. |
| Does a formulation name create a protocol? | It can identify a different compound design. | A self-directed dosing or titration rule. 3 4 |
Why body-weight calculators and social-media protocols can be misleading
A calculator may look precise because it produces a number. But precision is not the same as evidence. A body-weight formula cannot tell whether a person has a condition or medication that changes risk, whether the product matches its label, or whether any proposed use has been tested in humans. Reviews of unapproved peptide therapies caution that evidence, product quality, and safety oversight can vary. 3 4
For a closer look at why online tools can overstate certainty, see our guide to CJC-1295 and ipamorelin dosing calculators. Our overview of CJC-1295 and ipamorelin dosage evidence also explains the difference between a study finding and a personal treatment plan.
How do CJC-1295 with DAC and CJC-1295 no DAC differ?
CJC-1295 with DAC and CJC-1295 no DAC are described as different formulations, with DAC referring to drug affinity complex technology intended to alter how long a compound remains in circulation. Different formulation names do not create a safe self-dosing rule. The supplied evidence does not establish an approved or validated personal dosing conversion between these forms, especially when either is discussed with ipamorelin. 4 6
Why formulation names do not create a self-dosing rule
It is tempting to assume that a longer-acting design means a simple change in frequency or amount. That assumption skips key questions: which exact product is being discussed, what human data exist for that product, what outcome is being sought, and what adverse effects or interactions need monitoring. These gaps are why a product label, online forum, or social post is not a substitute for clinician oversight. 3 4
If you are comparing terminology, our article on CJC-1295 with DAC and ipamorelin explains why pharmacology language should not be mistaken for individualized prescribing advice.
What safety questions should be reviewed before using growth-hormone-releasing peptides?
A safety review should happen before any treatment decision, not after a chart has been chosen. A complete medication and health-history review helps a clinician weigh uncertain benefit against possible harm, particularly when evidence for an intended use is limited. 3 4 5
Medical history, concurrent medicines, and product source
- Discuss the goal you are trying to address and whether there is an established treatment with evidence for that goal. 4
- Bring a current list of prescription medicines, over-the-counter products, supplements, and other peptides for interaction review. 3 5
- Share relevant health history and prior reactions to medications so a clinician can assess contraindications and monitoring needs. 3 4
- Avoid treating a “research use only” listing, influencer post, or online calculator as evidence of prescription-grade sourcing or individual suitability. 4 5
Symptoms and concerns that warrant prompt medical attention
New, severe, or rapidly worsening symptoms after using any medication or injection deserve prompt medical evaluation. Symptoms of a severe allergic reaction, trouble breathing, fainting, severe chest symptoms, or severe abdominal symptoms warrant urgent care. Because combination-specific safety data are lacking, do not assume an unexpected symptom is normal or safe to manage with advice from a forum. 3 4
Are CJC-1295 and ipamorelin approved or established for wellness or anti-aging use?
The supplied evidence does not establish CJC-1295 plus ipamorelin as an FDA-approved or clinically established treatment for wellness or anti-aging use. Human ipamorelin research spans more than 25 years, but the cited studies do not validate this combination for longevity, body composition, or athletic performance. 1 2 4
How can you evaluate online CJC-1295 and ipamorelin access claims?
Look for clinical accountability rather than a promised protocol. Chia does not provide CJC-1295 or ipamorelin treatment access, and neither compound appears in our current treatment catalog. We think that is important to state plainly rather than implying that every peptide discussed online is available or appropriate.
When evaluating an online claim, ask whether it distinguishes human evidence from theory, states what has and has not been studied, and provides access to a licensed clinician for individualized review. Recent reviews note that unapproved peptide therapies can have meaningful evidence, safety, and sourcing limitations. 3 4 5
Questions to ask a licensed clinician and dispensing pharmacy
- What human evidence supports the specific use I am considering, rather than a different indication or a different peptide? 1 2
- What are the known and unknown risks, interactions, contraindications, and monitoring needs for my health history? 3 4
- Who is responsible for follow-up if I develop side effects or have questions about the product?
- Is the dispensing source a state-licensed pharmacy rather than an unregulated research-chemical seller? 4 5
- Does the seller clearly state when a product is compounded and therefore not FDA-approved?
For more on evaluating claims before purchasing peptides online, read our patient guide to finding a legitimate peptide source and our overview of peptide side effects.
What peptide care can Chia provide?
Chia does not offer CJC-1295, ipamorelin, or a CJC-1295/ipamorelin combination. For treatments in our catalog, care begins with a short online health questionnaire and review by a licensed US provider. A prescription is only issued when clinically appropriate and is never guaranteed.
Our currently available peptide-related options include sermorelin in injection, nasal-spray, and tablet forms, along with other cataloged treatments that may be relevant to different goals. Medications are compounded by state-licensed US 503A pharmacies, shipped to the patient’s door, and managed with provider-guided follow-up through the patient portal. Compounded medications are not FDA-approved.
A clinician can help you separate a specific goal from a trending protocol. That conversation may include whether an offered treatment is appropriate, whether another medical evaluation is needed, or whether the available evidence is too limited to support a treatment decision.
Frequently asked questions
No online dose can be assumed safe for you. The supplied evidence does not establish a validated starting-dose standard for the CJC-1295 and ipamorelin combination, and personal risks require a licensed clinician’s review.
No. The cited human studies examined growth hormone response in volunteers or postoperative gastrointestinal recovery, not anti-aging, athletic performance, body composition, or combined use with CJC-1295.
A formulation name does not establish a self-dosing conversion. The supplied evidence does not validate a personal dosing rule between CJC-1295 with DAC and CJC-1295 no DAC, especially in combination with ipamorelin.
Telehealth rules and prescribing decisions depend on the clinician, the patient’s location, the treatment, and clinical appropriateness. Chia does not offer CJC-1295, ipamorelin, or their combination.
Bring your goals, complete medication and supplement list, relevant health history, prior medication reactions, and information about any product you are considering. This helps the clinician review risks, interactions, and evidence limits.
No validated body-weight calculator is established by the supplied evidence for this combination. A calculator cannot account for your medical history, other medicines, formulation details, or monitoring needs.
The supplied studies do not establish the combination for muscle gain, longevity, body composition, or athletic performance. These claims should not be inferred from studies performed in other settings.
References
- 1.Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999.
- 2.Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014.
- 3.Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026.
- 4.Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026.
- 5.Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews. 2026.
- 6.Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. International Journal of Molecular Sciences. 2026.
- 7.ClinicalTrials.gov. Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus (NCT00672074). Completed phase 2 study. 2026.
- 8.ClinicalTrials.gov. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function (NCT01280344). Completed phase 2 study. 2026.
- 9.ClinicalTrials.gov. Trifecta Research Study (NCT07717866). Active, not recruiting study record. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.



